Long-Term Efficacy and Safety of Upadacitinib in Patients with Rheumatoid Arthritis: Final Results from the BALANCE-EXTEND Open-Label Extension Study

Long-Term Efficacy and Safety of Upadacitinib in Patients with Rheumatoid Arthritis: Final Results from the BALANCE-EXTEND Open-Label Extension Study

Abstract Introduction Upadacitinib (UPA) is an oral, selective Janus kinase inhibitor that has demonstrated favorable efficacy with an acceptable safety profile across a global, phase 3 program in rheumatoid arthritis (RA). This phase 2 open-label extension investigated the efficacy and safety of UP...

Full description

Bibliographic Details
Main Authors: Alan Kivitz, Alvin F. Wells, Juan I. Vargas, Herbert S. B. Baraf, Maureen Rischmueller, Justin Klaff, Nasser Khan, Yihan Li, Kyle Carter, Alan Friedman, Patrick Durez
Format: Article
Language:English
Published: Adis, Springer Healthcare 2023-05-01
Series:Rheumatology and Therapy
Subjects:
Extension
Janus kinase inhibitor
Phase 3
Rheumatoid arthritis
Treatment
Upadacitinib
Online Access:https://doi.org/10.1007/s40744-023-00557-x

Internet

https://doi.org/10.1007/s40744-023-00557-x

Similar Items